Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) EBT Margin (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed EBT Margin for 6 consecutive years, with 3413.03% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin fell 232006.0% to 3413.03% in Q4 2025 year-over-year; TTM through Dec 2025 was 892.02%, a 33567.0% decrease, with the full-year FY2025 number at 892.02%, down 33567.0% from a year prior.
  • EBT Margin was 3413.03% for Q4 2025 at Kymera Therapeutics, down from 3350.87% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 40.44% in Q4 2023 to a low of 3413.03% in Q4 2025.
  • A 5-year average of 848.68% and a median of 427.28% in 2022 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: surged 29870bps in 2021, then tumbled -232006bps in 2025.
  • Kymera Therapeutics' EBT Margin stood at 133.7% in 2021, then crashed by -79bps to 239.73% in 2022, then surged by 83bps to 40.44% in 2023, then plummeted by -2603bps to 1092.97% in 2024, then crashed by -212bps to 3413.03% in 2025.
  • Per Business Quant, the three most recent readings for KYMR's EBT Margin are 3413.03% (Q4 2025), 3350.87% (Q3 2025), and 737.76% (Q2 2025).